Oligomerix Receives $1.9 Million NIH Grant to Advance Oral Tau-Targeting Therapy for Alzheimer’s Disease Oligomerix, Inc., a privately held clinical-stage biotechnology company focused on developing novel treatments for Alzheimer’s disease and rare neurodegenerative disorders, has been awarded a $1.9 million…
Deciphera Pharmaceuticals Launches Global Phase 3 INTREPID Trial of Sapablursen for Polycythemia Vera Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd., has announced a significant milestone in the development of a potential new treatment for polycythemia vera (PV), with…
Jazz Pharmaceuticals and AbCellera Partner to Advance Next-Generation T-Cell Engaging Antibodies for Gastrointestinal and Solid Tumors Jazz Pharmaceuticals and AbCellera have entered into a strategic research collaboration aimed at discovering and developing a new generation of T-cell engaging (TCE) multispecific…
BioTools Innovator VANGUARD and BARDA Launch ReadyDetect Competition to Advance At-Home Blood Collection Technologies BioTools Innovator VANGUARD, in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), has announced the launch of the ReadyDetect: Blood Sampling Competition, a new…
Pelago Bioscience Expands Drug Discovery Capabilities Through Acquisition of RG Discovery Pelago Bioscience, a leading contract research organization (CRO) specializing in cell-based target engagement technologies, has announced the acquisition of RG Discovery, a Sweden-based drug discovery company recognized for its…
Takeda Presents New Phase 3 Data Showing Oveporexton Improves Daily Functioning, Cognition, and Sleep in Narcolepsy Type 1 Takeda has unveiled additional findings from its pivotal Phase 3 clinical development program for oveporexton (TAK-861) at SLEEP 2026, highlighting the investigational…
Incyte Reports Positive Phase 3 frontMIND Results Showing Tafasitamab and Lenalidomide Plus R-CHOP Improves Outcomes in High-Risk DLBCL and HGBL Incyte has announced positive results from its pivotal Phase 3 frontMIND clinical trial, demonstrating that the addition of tafasitamab and…
BeOne Medicines Showcases Promising Hematology Pipeline Data at EHA 2026, Highlighting Advances in BTK Degradation and Time-Limited Therapies BeOne Medicines Ltd., a global oncology company focused on developing innovative treatments for cancer and hematologic malignancies, has unveiled a series of…
Zetagen Therapeutics Reports Promising Phase 2a Results for Investigational ZetaMet™ in Metastatic Breast Cancer Patients With Lytic Bone Lesions Zetagen Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies for primary and metastatic breast cancer, has released updated preliminary…
BeOne Medicines Highlights Long-Term BRUKINSA Benefits in Older CLL Patients at EHA 2026 BeOne Medicines Ltd., a global oncology company dedicated to advancing innovative cancer therapies, has announced the presentation of significant new clinical and real-world evidence supporting the long-term…
Anocca Doses First Patients in VIDAR-1 Trial of ANOC-001 TCR-T Therapy for KRAS-Mutated Pancreatic Cancer Anocca AB, a clinical-stage biotechnology company focused on the development of advanced T-cell immunotherapies, has announced a major milestone in its clinical development efforts with…
Galderma Global Survey Reveals Rising Demand for Long-Lasting, Natural-Looking Anti-Wrinkle Treatments Galderma has unveiled the results of a major international survey examining the expectations, preferences, and experiences of both patients and healthcare professionals (HCPs) regarding anti-wrinkle aesthetic treatments. Conducted across…